{"id":"W2734451381","doi":"10.1200/jco.2017.35.15_suppl.4507","title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Pazopanib; Clinical endpoint; Placebo; Renal cell carcinoma; Tolerability; Internal medicine; Discontinuation; Nephrectomy; Adverse effect; Surgery; Intention-to-treat analysis; Phases of clinical research; Urology; Gastroenterology; Randomized controlled trial; Clinical trial; Kidney; Pathology; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001547109,0.001400947,0.002141633,0.0003584103,0.0003059618,0.0008037477,0.000644523,0.001159216,0.008375304],"category_scores_gemma":[0.001414242,0.0005724874,0.001394013,0.0003945303,0.0007347769,0.0007274266,0.0004126189,0.002438501,0.001205793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007056386,"about_ca_system_score_gemma":0.001301901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009457186,"about_ca_topic_score_gemma":0.003052691,"domain_scores_codex":[0.9995441,0.0002695401,0.00002114779,0.00006625977,0.0000351587,0.00006386937],"domain_scores_gemma":[0.9993917,0.0001419344,0.0001825634,0.00004487472,0.00003706557,0.0002019177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9788744,0.002970199,0.0006051961,0.0005122274,0.0006019854,0.00003644262,0.00003062491,0.00038001,0.001924645,0.0001208628,0.001272846,0.0126704],"study_design_scores_gemma":[0.9581161,0.03907543,0.001223368,0.0000214245,0.00024594,0.00003896424,0.00001063103,0.0002833156,0.0001867656,0.0001344694,0.000657749,0.000005903555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751373,0.006547466,0.001069976,0.001101796,0.0008708543,0.006572036,0.003943406,0.0002631143,0.004493965],"genre_scores_gemma":[0.9792727,0.003052749,0.001830423,0.001526718,0.0004472165,0.00611067,0.00319336,0.00002947185,0.004536515],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008375304,"threshold_uncertainty_score":0.02801824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06148641616435672,"score_gpt":0.3987801206706259,"score_spread":0.3372937045062692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}